Golimumab improves patient-reported outcomes in daily practice of inflammatory rheumatic diseases in Germany.
Conclusion: Golimumab induces sustained improvements in WPAI and QoL and reduces healthcare resource utilization in RA, PsA and AS.
PMID: 32722921 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research
More News: Ankylosing Spondylitis | Arthritis | General Medicine | Germany Health | Psoriatic Arthritis | Rheumatoid Arthritis | Rheumatology | Study